| Name | potassium,5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate |
|---|---|
| Synonyms |
HCV,VCH 916,VCH916,Hatitis C virus,VCH-916,inhibit,Inhibitor
VCH-916 (Free) VCH 916 Potassium 5-(cyclohex-1-en-1-yl)-3-(trans-N-(trans-4-methoxycyclohexyl)-4-methylcyclohexane-1-cboxamido)thiophene-2-cboxylate VCH-916, >= S1493_Selleck CS-1224 Potassium 5-(1-cyclohexen-1-yl)-3-{(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-2-thiophenecarboxylate potassiuM 5-cyclohexenyl-3-(N-((1r,4r)-4-Methoxycyclohexyl)-4-MethylcyclohexanecboxaMido)thiophene-2-cboxylate 5-(1-Cyclohexen-1-yl)-3-[(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-2-thiophenecboxylic acid potassium salt VCH 916;VCH 2-Thiophenecarboxylic acid, 5-(1-cyclohexen-1-yl)-3-[(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-, potassium salt (1:1) VCH-916||VCH 916 |
| Description | VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.IC50 Value: Target: HCVVCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C26H36KNO4S |
|---|---|
| Molecular Weight | 497.732 |
| Exact Mass | 497.200226 |
| PSA | 97.91000 |
| LogP | 5.18590 |
| Storage condition | 2-8℃ |